This is a great era to be making generic drugs. With Wal-Mart selling them for $4 and insurance formularies increasingly favoring generics, this segment of the pharmaceutical world is on the upswing at a time when big, research-based drug companies are having trouble developing new blockbusters.
About 67% of the U.S.'s prescription volume is now generics, according to IMS Health. This puts generic-drug giants, such as Mylan Laboratories (symbol MYL), in an enviable position.
Mylan is doing its best to take advantage of this favorable environment. It has always had a formidable business in the U.S., run from Canonsburg, Pa. But it recently bought the generic-drug business of Germany's Merck KgaA (not to be confused with Merck in the U.S.), making Mylan a player in Europe and the third-biggest generic-drug company worldwide. An agreement with Famy Care of India to manufacture a slew of generic oral contraceptives and the purchase of Matrix, an Indian generics maker, gives Mylan access to lower labor costs in that country.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
But Mylan's growth spurt came at a price. Nearly debt-free as recently as 2006, the company now owes almost $5 billion -- this at a time when credit markets around the world are cranky, to say the least. "That's one of the risks of the stock," notes analyst Martha Freitag of Argus Research. "This is a riskier investment idea than a company that has a conservative balance sheet." Most of Mylan's financing is in place, however.
Freitag upgraded the stock from "hold" to "buy" on September 30 on the strength of Mylan's product launches and its slim valuation -- the stock closed at $10.27 on October 3, down more than 60% from a year ago.
The debt load forced Mylan to suspend its dividend and dilute shareholder value by issuing an additional $3 billion in equity financing last year.
Mylan had hoped to sell Dey, its specialty-pharmaceutical division. But the business didn't fetch the price that Mylan was seeking, so Dey is off the sale block. The firm planned to use the proceeds from that sale to pay down debt. "The Dey transaction would have made me much more comfortable with the debt level," says Morningstar analyst Brian Laegeler, who thinks that Mylan should sell Dey for whatever price it can in order to make headway on the debt.
Yet Laegeler thinks the acquisitions ultimately put Mylan on the right path. "What people are missing is the large amount of cost saving that is going to come through in the next three to five years," he says. "And that's going to help them pay off the debt."
Mylan can increase sales and ultimately earnings through various channels. The firm recently launched several new products, including Johnson & Johnson's Alzheimer's and antipsychotic medications, Razadyne and Risperdal, respectively.
In 2011, a number of blockbuster drugs held by the big pharmaceutical companies come off patent, including Pfizer's Lipitor, a cholesterol-lowering drug, and Plavix, a medication for blood clots. Generic biologics, which are still five years away from market debut, would give Mylan yet another avenue. And both presidential candidates vow to make generic drugs a big piece of their health-care reform plans as a way to contain costs.
And then there's that attractive valuation. On average, analysts expect the company to earn 99 cents a share in 2009 -- double the anticipated 2008 earnings of 50 cents. That puts its price-earnings ratio for this year's profits at a reasonable 20 and for next year's at a very tempting 11, which is one of the lowest among the general drug clan. "At this valuation," says Argus's Freitag, "the risks are fairly well recognized."
-
The Rule of Two Lives in Retirement: A Retirement RuleThe 'rule of two lives in retirement' means accounting for your partner at every decision point, because one life becomes two.
-
Retire in This Asian Country for a Warm Culture and Relaxed LifestyleWith its fabulous beaches, delicious food, and affordability, this Southeast Asian country is a haven for expats from around the world.
-
If You'd Put $1,000 Into UnitedHealth Group Stock 20 Years Ago, Here's What You'd Have TodayUNH stock was a massive market beater for ages – until it wasn't.
-
What Tariffs Mean for Your Sector ExposureNew, higher and changing tariffs will ripple through the economy and into share prices for many quarters to come.
-
How to Invest for a Fall Interest Rate Cut by the FedA lot can happen between now and then, but the probability the Fed cuts interest rates in September is back above 80%.
-
Are Buffett and Berkshire About to Bail on Kraft Heinz Stock?Warren Buffett and Berkshire Hathaway own a lot of Kraft Heinz stock, so what happens when they decide to sell KHC?
-
How the Stock Market Performed in the First 6 Months of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Berkshire Hathaway Stock 20 Years Ago, Here's What You'd Have TodayBerkshire Hathaway is a long-time market beater, but the easy money in BRK.B has already been made.
-
If You'd Put $1,000 Into Procter & Gamble Stock 20 Years Ago, Here's What You'd Have TodayProcter & Gamble stock is a dependable dividend grower, but a disappointing long-term holding.
-
My Three-Day Rule for Investing: And If it Applies NowStock Market I've seen a lot in my career. Here's what I see now in the stock market.
